Jakob Dupont - Nov 16, 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
EVP, Head of R&D
Signature
/s/ Jeff Kiekhofer, Attorney-in-Fact for Jakob Dupont
Stock symbol
ATRA
Transactions as of
Nov 16, 2022
Transactions value $
-$19,497
Form type
4
Date filed
11/18/2022, 07:13 PM
Previous filing
Oct 3, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Sale -$14.4K -3.22K -2.03% $4.49 156K Nov 16, 2022 Direct F1, F2
transaction ATRA Common Stock Sale -$5.05K -1.12K -0.72% $4.49 155K Nov 16, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney